Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetic, Safety, Tolerability, and Immunogenicity Study of SB8 in Healthy Male Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male subjects~* Have body weight between 65.0-90.0 kg (inclusive) and body mass index between 20.0-29.9 kg/m2 (inclusive)~Exclusion Criteria:~* Have a history of hypersensitivity or allergic reactions to bevacizumab or to any of the excipients~* Have a history of and/or current clinically significant gastrointestinal, renal, hepatic, cardiovascular, haematological, pulmonary, neurologic, metabolic, psychiatric, or allergic disease excluding mild asymptomatic seasonal allergies~* Have a history of arterial thromboembolic events including cerebrovascular accidents, transient ischaemic attacks, and myocardial infarction~* Have a history of and/or current cardiac disease~* Have previously been exposed to vascular endothelial growth factor (VEGF) antibody, any other antibody, or protein targeting the VEGF receptor~* Have a history of cancer including lymphoma, leukaemia, and skin cancer.~* Have received live vaccine(s) within 30 days prior to Screening visit or who will require a vaccine(s) between Screening and the end of study visit~* Have taken medication with a half-life of \> 24 hours within 30 days or 10 half-lives of the medication prior to the IP administration

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- SB8 (Type: EXPERIMENTAL): SB8, single dose of 3 mg/kg, IV infusion
- EU Sourced Avastin® (Type: ACTIVE_COMPARATOR): EU Sourced Avastin®, single dose of 3 mg/kg, IV infusion
- US Sourced Avastin® (Type: ACTIVE_COMPARATOR): US Sourced Avastin®, single dose of 3 mg/kg, IV infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).